Welcome to our dedicated page for Kezar Life Sciences news (Ticker: KZR), a resource for investors and traders seeking the latest updates and insights on Kezar Life Sciences stock.
Kezar Life Sciences, Inc. (Nasdaq: KZR) is a clinical-stage biopharmaceutical company developing novel small molecule therapeutics for immune-mediated diseases, with a primary focus on its lead candidate zetomipzomib. The KZR news feed on Stock Titan aggregates company-issued press releases and other coverage so readers can follow how Kezar’s clinical programs and corporate decisions evolve over time.
Much of Kezar’s recent news centers on zetomipzomib, a first-in-class, selective immunoproteasome inhibitor. Updates include topline and Phase 2a data from the PORTOLA trial in autoimmune hepatitis, regulatory developments such as the lifting of a partial clinical hold and subsequent FDA feedback on future trial requirements, and presentations of efficacy and biomarker data at major medical meetings. The company has also reported safety and preliminary efficacy findings from the PALIZADE Phase 2b trial in lupus nephritis.
Investors and observers will find earnings and financial results releases that detail research and development spending, general and administrative expenses, restructuring and impairment charges, and reported net losses typical of a clinical-stage enterprise. Kezar’s announcements also describe its strategic review process, workforce reduction and cost-containment measures, repayment and termination of a loan agreement, and the adoption and extension of a shareholder rights plan.
By reviewing KZR news, readers can track clinical milestones, regulatory interactions with the U.S. Food and Drug Administration, participation in healthcare investment conferences, and governance developments such as annual meeting outcomes. This context helps frame how clinical data, capital allocation and strategic alternatives may influence the company’s trajectory. Bookmark this page to follow ongoing disclosures and historical updates related to Kezar Life Sciences.
Kezar Life Sciences (KZR) has announced a public offering of 7,590,909 shares of common stock at a price of $5.50 per share, along with 909,091 pre-funded warrants priced at $5.499, aiming for gross proceeds of $46.7 million. A 30-day option for underwriters to purchase an additional 1,275,000 shares has been granted. Proceeds will mostly fund R&D and potential acquisitions. The offering is set to close on June 11, 2020, subject to standard closing conditions. The offering is registered under an SEC effective shelf registration statement.
Kezar Life Sciences, Inc. (Nasdaq: KZR) announced promising results from its Phase 1b study of KZR-616 for treating systemic lupus erythematosus (SLE) and lupus nephritis. Among two lupus nephritis patients, both experienced over 50% reduction in proteinuria. Overall, the study showed improvements in seven disease activity measures, indicating positive exploratory efficacy data. The safety profile of KZR-616 was favorable, with no treatment discontinuations reported. Encouraged by the results, Kezar aims to expedite the development of KZR-616 for severe autoimmune diseases.
Kezar Life Sciences announced that its executive team will participate in a Fireside Chat at the Jefferies Virtual Healthcare Conference on June 4, 2020, at 1:30 PM EDT. The event will be accessible via live webcast through the company's website, with an archived replay available for 90 days post-conference. Kezar focuses on innovative therapies for autoimmune diseases and cancer, with candidates like KZR-616 and KZR-261 in development.
Kezar Life Sciences (Nasdaq: KZR) announced significant presentations at major upcoming scientific conferences, highlighting their innovative therapeutic programs. Three abstracts have been accepted, showcasing the preclinical data for KZR-261 targeting solid tumors and the promising clinical data for KZR-616 in treating severe autoimmune diseases. Notably, these presentations include details about clinical trials and findings that underscore the potential of these compounds in their respective therapeutic areas.
Kezar Life Sciences (KZR) announced key updates in its Q1 2020 financial results and corporate activities. Noreen R. Henig, MD, has been appointed as Chief Medical Officer, enhancing the leadership team. The company reported cash and equivalents of $123 million as of March 31, 2020, a notable increase from $78.2 million in Q4 2019. Ongoing clinical trials for KZR-616 are active, despite anticipated delays due to COVID-19. Additionally, KZR-261's IND submission is on track for Q1 2021, with new data presentation planned at ASCO 2020.
Kezar Life Sciences (KZR) announced the appointment of Dr. Noreen R. Henig as Chief Medical Officer on May 4, 2020. Dr. Henig brings extensive experience in clinical development and medical affairs, having previously served as CMO at Breath Therapeutics and ProQR Therapeutics. Her role will involve overseeing clinical development and regulatory aspects at Kezar, which focuses on novel therapeutics for autoimmune diseases and cancer. CEO John Fowler praised her leadership and expertise in immunology, indicating her potential to positively influence the company's growth and patient engagement.